Free Trial

Alto Neuroscience (ANRO) Competitors

Alto Neuroscience logo
$2.94 +0.10 (+3.33%)
Closing price 05/22/2025 03:59 PM Eastern
Extended Trading
$2.90 -0.04 (-1.53%)
As of 05/22/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ANRO vs. RNAC, TSVT, ALMS, INZY, GLUE, TERN, PVLA, LFCR, TNGX, and GOSS

Should you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Alumis (ALMS), Inozyme Pharma (INZY), Monte Rosa Therapeutics (GLUE), Terns Pharmaceuticals (TERN), Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR), Tango Therapeutics (TNGX), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry.

Alto Neuroscience vs.

Alto Neuroscience (NYSE:ANRO) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings.

86.9% of Cartesian Therapeutics shares are owned by institutional investors. 11.1% of Alto Neuroscience shares are owned by insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alto Neuroscience has higher earnings, but lower revenue than Cartesian Therapeutics. Alto Neuroscience is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alto NeuroscienceN/AN/A-$36.31M-$2.34-1.26
Cartesian Therapeutics$34.17M6.95-$219.71M-$52.83-0.17

Cartesian Therapeutics received 23 more outperform votes than Alto Neuroscience when rated by MarketBeat users. Likewise, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 80.00% of users gave Alto Neuroscience an outperform vote.

CompanyUnderperformOutperform
Alto NeuroscienceOutperform Votes
16
80.00%
Underperform Votes
4
20.00%
Cartesian TherapeuticsOutperform Votes
39
95.12%
Underperform Votes
2
4.88%

In the previous week, Alto Neuroscience had 6 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 19 mentions for Alto Neuroscience and 13 mentions for Cartesian Therapeutics. Alto Neuroscience's average media sentiment score of 0.64 beat Cartesian Therapeutics' score of 0.42 indicating that Alto Neuroscience is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alto Neuroscience
4 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cartesian Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Alto Neuroscience has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.

Alto Neuroscience has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat Alto Neuroscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Alto NeuroscienceN/A -49.28% -33.52%
Cartesian Therapeutics -510.72%N/A -6.03%

Alto Neuroscience presently has a consensus target price of $15.40, indicating a potential upside of 422.92%. Cartesian Therapeutics has a consensus target price of $42.50, indicating a potential upside of 364.48%. Given Alto Neuroscience's higher probable upside, analysts clearly believe Alto Neuroscience is more favorable than Cartesian Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alto Neuroscience
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57
Cartesian Therapeutics
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75

Summary

Cartesian Therapeutics beats Alto Neuroscience on 10 of the 17 factors compared between the two stocks.

Get Alto Neuroscience News Delivered to You Automatically

Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ANRO vs. The Competition

MetricAlto NeurosciencePharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$79.73M$6.47B$5.33B$19.30B
Dividend YieldN/A2.64%5.21%3.83%
P/E Ratio-1.269.0626.7134.53
Price / SalesN/A251.51386.0834.83
Price / CashN/A65.8538.2517.51
Price / BookN/A6.456.774.69
Net Income-$36.31M$143.98M$3.23B$1.02B
7 Day Performance20.70%2.41%1.80%-1.74%
1 Month Performance31.41%4.56%11.10%7.50%
1 Year Performance-76.04%-2.67%17.11%4.15%

Alto Neuroscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ANRO
Alto Neuroscience
1.7019 of 5 stars
$2.95
+3.3%
$15.40
+422.9%
-76.0%$79.73MN/A-1.26N/ANews Coverage
Analyst Revision
RNAC
Cartesian Therapeutics
1.5293 of 5 stars
$10.37
+1.1%
$42.50
+309.8%
-64.1%$269.14M$34.17M-0.2064News Coverage
Analyst Revision
Gap Up
TSVT
2seventy bio
1.5355 of 5 stars
$5.00
flat
$4.25
-15.0%
N/A$266.15M$48.37M-2.69440Positive News
ALMS
Alumis
2.2312 of 5 stars
$5.95
+5.9%
$24.86
+317.8%
N/A$265.38MN/A0.00N/AGap Down
INZY
Inozyme Pharma
3.0315 of 5 stars
$3.99
+1.0%
$11.75
+194.5%
-15.4%$257.60MN/A-2.5650High Trading Volume
GLUE
Monte Rosa Therapeutics
2.1238 of 5 stars
$4.11
+3.3%
$15.50
+277.1%
-3.8%$252.81M$159.49M-2.2590Positive News
Analyst Downgrade
TERN
Terns Pharmaceuticals
4.0922 of 5 stars
$3.15
+9.4%
$15.63
+396.0%
-50.4%$251.53MN/A-2.6740News Coverage
Positive News
PVLA
Palvella Therapeutics
3.7974 of 5 stars
$22.56
+2.3%
$46.29
+105.2%
N/A$249.13M$42.81M-1.86N/AAnalyst Revision
LFCR
Lifecore Biomedical
1.1994 of 5 stars
$6.71
-2.6%
$8.00
+19.2%
+14.4%$248.44M$130.31M-11.98690News Coverage
Analyst Forecast
Gap Up
TNGX
Tango Therapeutics
1.878 of 5 stars
$2.29
+52.7%
$12.33
+438.6%
-74.8%$248.22M$40.99M-1.9490Positive News
High Trading Volume
GOSS
Gossamer Bio
3.75 of 5 stars
$1.09
+4.8%
$7.75
+611.0%
+81.7%$247.67M$114.70M-3.41180Analyst Revision

Related Companies and Tools


This page (NYSE:ANRO) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners